Emergency Visits or Hospitalizations for Cardiovascular Diagnoses in the Post-Acute Phase of COVID-19
Study context
- Population
- All adults in Alberta tested for SARS-CoV-2 by RT-PCR, March 1, 2020–June 30, 2021matched cohort
- Exposure
- SARS-CoV-2 positive vs matched test-negative controls
- Casesn = 177,892
- Outcome
- ED visit or hospitalization for CV diagnoses in the postacute phase
- Follow-up
- After 3 months
Methodological detailsmatched (age, sex, Charlson Comorbidity score, test date)
- Matched (age, sex, Charlson Comorbidity score, test date)
Main finding
As reported in the abstract
ED visit or hospitalization, postacute phase
DM
Hypertension
HF
Kidney injury
Observational data: associations, not effects.
Further findings
ED visit, hospitalisation or death within 1 month
- ED visit, SARS-CoV-2 positive vs matched test-negative controls
- 5.7% vs 3.3%
- Hospitalised, SARS-CoV-2 positive vs matched test-negative controls
- 3.4% vs 2.1%
- Death, SARS-CoV-2 positive vs matched test-negative controls
- 1.3% vs 0.4%
- Matched cohort
Post-acute ED visit or hospitalisation, survivors of COVID-19 hospitalisation (subgroup, n = 6,030) · postacute phase
aOR
- DM: 9.5% vs 3.0%
- 3.16 (95% CI 2.43-4.12)
- Hypertension: 3.5% vs 1.4%
- 2.89 (95% CI 1.97-4.23)
- HF: 2.1% vs 0.7%
- 3.16 (95% CI 1.88-5.29)
- Kidney injury: 3.1% vs 0.8%
- 2.70 (95% CI 1.71-4.28)
- Bleeding: 1.5% vs 0.5%
- 3.40 (95% CI 1.83-6.32)
- VTE: 0.8% vs 0.3%
- 3.60 (95% CI 1.59-8.13)
Original publication
Emergency Visits or Hospitalizations for Cardiovascular Diagnoses in the Post-Acute Phase of COVID-19. JACC Adv. Published 5 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →